Men diagnosed with favorable risk prostate cancer are recommended for Active Surveillance (AS). AS is a method of safely monitoring one’s conditions for possible progression to the stage at which an aggressive intervention becomes the new recommendation.
Low-risk men on AS are at the same risk level for progression or mortality as similarly classified men who pursue immediate aggressive treatment, but over the long term half or more of men on AS never need aggressive treatment. Moreover, men who do pursue immediate aggressive treatment for low-risk PC often subject themselves to a lower quality of life due to side effects, and/or other secondary medical procedures seeking to correct unfavorable primary PC treatment outcomes, while experiencing no prostate cancer-specific benefit.
The uptake of AS in the U.S. is now approaching 50% of eligible men, but that means 50% are pursue medically unnecessary, immediate aggressive treatments (most commonly surgery, or radiation therapy). Today, Medicare or private insurance provides high reimbursement coverage for aggressive PC treatments, even in the cases described here as medically unnecessary.
Under current regulations, if Medicare pays for an unnecessary procedure, every tax-paying American contributes additional tax revenue for that event. If private insurance pays for an unnecessary procedure, then again “we” collectively (although not so uniformly as through taxes) pay through greater wage reduction for higher insurance premiums.
A 2015 article in the New Yorker titled “
Overkill http://www.newyorker.com/magazine/2015/05/11/overkill-atul-gawande” (and numerous other recent similar articles) highlighted that millions of Americans get tests, drugs, and operations that won’t make them better, may cause harm, and cost billions…low-risk prostate cancer was amongst the specific illnesses discussed. Other medical articles have estimated that the cost of PC overtreatment alone is more than $1 billion per year in the U.S. At 17% of GDP and growing, the U.S. healthcare system is (by far) the most expensive in the world (and ranked 11th globally in quality of care).
LINK http://www.pbs.org/newshour/rundown/health-costs-how-the-us-compares-with-other-countries/ Naturally, challenging questions are being asked about
overspending, and low-risk prostate cancer overtreatment is increasingly being discussed as a candidate for reduced spending.
So, how do you feel about
paying for large numbers of “elective” procedures? Should Medicare/insurance coverage be reduced or eliminated for unnecessary medical treatments? Should we continue without changes?
Discuss merits